HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon.

Abstract
The crucial role of the von Willebrand Factor (vWF) and its interaction with platelets in myeloproliferative disorders (MPD) have emerged in recent years. Recently, many authors have reported the therapeutical efficacy of interferon (IFN) in MPD with thrombocytosis in decreasing platelet number. The purpose of our report is to study the modifications of vWF in a series of 20 patients affected by essential thrombocythemia (ET) or MPD with thrombocytosis, treated with alpha 2b recombinant IFN (alpha 2b-rIFN). Patients were studied before treatment and after complete or partial response: vWF-related properties, bleeding time (BT) and ristocetin-induced platelet aggregation (RIPA) were evaluated. Before treatment, we found prolonged BT in 5 patients (25%), abnormal RIPA in 8 (40%), reduced factor VIII coagulant activity (VIII:C) in 2 (10%), reduced vWF-related antigen (vWF:Ag) in 5 (25%) and low vWF:ristocetin cofactor (vWF:Ricof) in 5 (25%). Twelve subjects were evaluated after hematologic remission: in all patients, BT, VIII:C, vWF:Ag and vWF:Ricof were within normal range or upper normal limits. RIPA was abnormal in 7 subjects. Multimer patterns of vWF were performed in 3 patients before and after treatment: 2 of them showed loss of high-molecular-weight multimers that seemed to recover at remission. IFN seems to induce improvement of platelet number and their functions in MPD with thrombocytosis.
AuthorsM G Mazzucconi, A Ferrari, S Solinas, A Vitale, A Chistolini, A B Federici, F Mandelli
JournalHaemostasis (Haemostasis) Vol. 21 Issue 3 Pg. 135-40 ( 1991) ISSN: 0301-0147 [Print] SWITZERLAND
PMID1773983 (Publication Type: Journal Article)
Chemical References
  • Interferon-alpha
  • Recombinant Proteins
  • von Willebrand Factor
  • interferon alfa-2b
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Interferon-alpha (therapeutic use)
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Thrombocythemia, Essential (blood, drug therapy)
  • von Willebrand Factor (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: